HR 5160: Stem Cell Therapeutic and Research Reauthorization Act of 2025

HR 5160 in plain English: This bill reauthorizes through FY2031 federal programs that help patients receive bone marrow and umbilical cord blood transplants from unrelated donors, administered by the Health Resources and Services Administration. It also revises the National Cord Blood Inventory program by replacing a fixed inventory goal of 150,000 units with a flexible supply standard determined by HRSA. Funding levels are set at $31,009,000 for an initial period and $33,009,000 per year for FY2027 through FY2031.

Stated purpose

To reauthorize through fiscal year 2031 the federal programs that help patients find and receive bone marrow and umbilical cord blood transplants from unrelated donors, and to update how the national cord blood supply is managed and measured.

Key points

• Reauthorizes the C.W. Bill Young Cell Transplantation Program through FY2031
• Sets funding at $33,009,000 per year for fiscal years 2027 through 2031
• Replaces the fixed inventory goal of 150,000 cord blood units with a flexible supply level set by HRSA
• Requires HRSA to manage inventory size and composition to maximize clinical utility and efficiency
• Updates the definition of a high-quality cord blood unit to meet current FDA and industry standards

Arguments supporters make

• Keeping these programs funded ensures patients who need a life-saving transplant but have no matching family donor still have a real chance of finding one.
• Replacing a fixed inventory number with a flexible, science-based goal lets the government focus resources on the cord blood units most likely to actually help patients.
• The updated quality definition tied to FDA and current industry standards helps ensure transplanted units are safe and effective.

Arguments opponents make

• Giving the Secretary broad discretion to set inventory size and dispose of stored units removes a concrete, measurable commitment that held the program accountable.
• The modest funding increase may not keep pace with rising costs, potentially limiting how many donations are collected or how well banks are supported.
• Removing the requirement to store units 'in perpetuity' could lead to discarding units that might have future value as science and patient needs evolve.

Tradeoffs

Flexibility in managing the cord blood inventory may improve efficiency and clinical usefulness, but it trades away a specific numerical target that gave the program a clear, checkable goal. Increased funding extends vital services, but moves decision-making power over what counts as 'sufficient' supply from Congress to the executive branch.

Current status in Congress: Passed House.

NewsClear — neutral news & congressional tracking · Bill of the Week